[1]张芝瑞,张 艳,李俊杰,等.慢性阻塞性肺疾病并发肺动脉高压患者血清微小RNA-130a、中性粒细胞与淋巴细胞比值、胸部血管CT参数变化及其与病情程度关系研究[J].陕西医学杂志,2024,(12):1640-1644.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.010]
　ZHANG Zhirui,ZHANG Yan,LI Junjie,et al.Changes of serum miR-130a,NLR and CT parameters of thoracic vessels in patients with COPD complicated with PAH and their relationship with disease severity[J].,2024,(12):1640-1644.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.010]
点击复制

慢性阻塞性肺疾病并发肺动脉高压患者血清微小RNA-130a、中性粒细胞与淋巴细胞比值、胸部血管CT参数变化及其与病情程度关系研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1640-1644
栏目:
临床研究
出版日期:
2024-12-05

文章信息/Info

Title:
Changes of serum miR-130a,NLR and CT parameters of thoracic vessels in patients with COPD complicated with PAH and their relationship with disease severity
作者:
张芝瑞; 张 艳; 李俊杰; 黄 杨; 王玉同; 赵 威; 张 斌
(空军军医大学第一附属医院,陕西 西安 710032)
Author(s):
ZHANG Zhirui; ZHANG Yan; LI Junjie; HUANG Yang; WANG Yutong; ZHAO Wei; ZHANG Bin
(The First Affiliated Hospital of Air Force Medical University,Xi'an 710032,China)
关键词:
慢性阻塞性肺疾病;  肺动脉高压;  微小RNA-130a;  中性粒细胞;  淋巴细胞
Keywords:
COPD;  Pulmonary arterial hypertension;  miR-130a;  Neutrophils;  Lymphocytes
分类号:
R 563.9
DOI:
DOI:10.3969/j.issn.1000-7377.2024.12.010
文献标志码:
A
摘要:
目的:探讨慢性阻塞性肺疾病(COPD)并发肺动脉高压(PAH)患者血清微小RNA-130a(miR-130a)、中性粒细胞与淋巴细胞比值(NLR)、胸部血管CT参数变化及其与病情程度的关系。方法:选取COPD并发PAH患者103例为COPD+PAH组,选取COPD但不并发PAH患者107例为COPD组,比较两组血清miR-130a、NLR、肺血管CT参数、肺功能及肺动脉收缩压。根据PAH程度将103例COPD+PAH组患者进一步分为轻度组、中度组和重度组,比较三组血清miR-130a、NLR和胸部血管CT参数。分析COPD并发PAH患者肺动脉收缩压与miR-130a、NLR、胸部血管CT参数的相关性。结果:COPD+PAH组血清miR-130a、NLR水平以及肺动脉直径(MPAD)、降主动脉直径(DAD)、升主动脉直径(AAD)高于COPD组(均P<0.05)。COPD+PAH组肺动脉收缩压高于COPD组,肺一氧化碳弥散能力(DLCO)预计值低于COPD组(均P<0.05)。重度组miR-130a、NLR水平以及MPAD、DAD、AAD高于中度组和轻度组,且中度组上述指标高于轻度组(均P<0.05)。COPD并发PAH患者肺动脉收缩压与miR-130a、NLR、MPAD、DAD、AAD呈正相关(均P<0.05)。结论:COPD并发PAH患者miR-130a、NLR水平升高,肺部MPAD、DAD、AAD增大,并且与患者PAH程度关系密切。
Abstract:
Objective:To explore the changes of serum miR-130a,neutrophil to lymphocyte ratio(NLR)and CT parameters of thoracic vessels in patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary arterial hypertension(PAH)and their relationship with disease severity.Methods:A total of 103 patients with COPD complicated with PAH were selected as the COPD+PAH group,and 107 patients with COPD but without PAH were selected as the COPD group.The serum miR-130a,NLR,pulmonary vascular CT parameters,pulmonary function and pulmonary artery systolic pressure were compared between the two groups.According to the degree of PAH,103 patients in the COPD+PAH group were further divided into mild group,moderate and severe groups,and the serum miR-130a,NLR and pulmonary vascular CT parameters were compared among the three groups.The correlation between pulmonary artery systolic pressure and miR-130a,NLR,CT parameters of thoracic vessels in COPD patients with PAH was analyzed.Results:Compared with the COPD group,the COPD+PAH group had significantly higher levels of miR-130a,NLR,MPAD,DAD and AAD(all P<0.05).Pulmonary artery systolic pressure in COPD+PAH group was higher than that in COPD group,and lung DLCO estimated value was lower than that in COPD group(all P<0.05).The levels of miR-130a,NLR,MPAD,DAD and AAD in the severe group were higher than those in the moderate and mild groups,and the above indexes in the moderate group were higher than those in the mild group(all P<0.05).Pulmonary artery systolic pressure was positively correlated with miR-130a,NLR,MPAD,DAD and AAD in patients with COPD complicated with PAH(all P<0.05).Conclusion:The levels of miR-130a and NLR in COPD patients with PAH are increased,and MPAD,DAD and AAD are increased,which are closely related to the degree of PAH in patients.

参考文献/References:

[1] CHRISTENSON S A,SMITH B M,BAFADHEL M,et al.Chronic obstructive pulmonary disease[J].Lancet,2022,399(10342):2227-2242.
[2] 张炜,王彧.揿针治疗肺肾气虚型慢性阻塞性肺疾病稳定期疗效研究[J].陕西中医,2024,45(1):115-119.
[3] OLSSON K M,CORTE T J,KAMP J C,et al.Pulmonary hypertension associated with lung disease:New insights into pathomechanisms,diagnosis,and management[J].Lancet Respir Med,2023,11(9):820-835.
[4] 张静,杨晔,董超,等.计算机断层扫描联合血清三叶因子1、微RNA-130a-5p检测对肺癌的诊断价值分析[J].安徽医药,2023,27(5):989-992.
[5] 邓超,卫艳,李贤英,等.血尿酸、B型脑钠肽及中性粒细胞/淋巴细胞比值水平在慢性阻塞性肺疾病并发肺动脉高压中的表达及其意义[J].实用医院临床杂志,2022,19(4):159-161.
[6] 杨俊囡,李甜甜,吴梅,等.血清炎症标志物在间质性肺病相关肺动脉高压中的临床意义[J].中国临床保健杂志,2023,26(1):119-122.
[7] 张兆福,李晓冬,王钺.CT肺小血管分析在慢性阻塞性肺疾病患者合并严重肺动脉高压中的作用[J].实用放射学杂志,2021,37(1):51-54.
[8] 陈江,段军杉.胸部CT对慢性阻塞性肺疾病合并肺动脉高压的分级诊断价值分析[J].贵州医药,2022,46(11):1801-1802.
[9] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.
[10] BOUSSEAU S,SOBRANO F R,Gu S,et al.Pathophysiology and new advances in pulmonary hypertension[J].BMJ Med,2023,2(1):e000137.
[11] 王雅宁,米婷,周红.不同通气模式治疗慢性阻塞性肺疾病合并呼吸衰竭临床疗效及患者呼吸动力学、肺功能水平比较[J].陕西医学杂志,2023,52(1):36-39,44.
[12] 吕玉颖,曹志新,马玉平.无创通气间歇期经鼻高流量湿化氧疗治疗慢性阻塞性肺疾病急性加重临床效果及对患者气管插管率、血气指标的影响[J].陕西医学杂志,2024,53(7):922-925,957.
[13] 文思敏,范玉琴,朱建平,等.名中医张震从虚、痰、瘀辨治慢性阻塞性肺疾病经验[J].陕西中医,2024,45(4):532-535,540.
[14] ATCHLEY W T,KAKKERA T K.Pulmonary hypertension in chronic obstructive pulmonary disease:Current understanding,knowledge gaps and future directions[J].Curr Opin Pulm Med,2024,30(2):150-155.
[15] CHRISTENSON S A.COPD phenotyping[J].Respir Care,2023,68(7):871-880.
[16] KOVACS G,AVIAN A,BACHMAIER G,et al.Severe pulmonary hypertension in COPD:Impact on survival and diagnostic approach[J].Chest,2022,162(1):202-212.
[17] 况宇,宋胜军,卢宗瑜,等.恶性胸腔积液细胞游离miR-130a与非小细胞肺癌患者生存的关系[J].广西医科大学学报,2022,39(12):2007-2013.
[18] 王潇,典万康,付守芝,等.血清miR-130a表达水平与COPD急性加重期患者近期预后不良的临床关系[J].中国急救复苏与灾害医学杂志,2024,19(1):77-80,105.
[19] WANG M,SU L,SUN J,et al.FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130,which targets PPARγ[J].J Cell Mol Med,2022,26(4):1034-1049.
[20] FAN Q,BAO X,ZHAO H,et al.LncRNA MRPL39 inhibits cell proliferation and migration by regulating miR-130/TSC1 axis in non-small cell lung cancer[J].Biotech,2024,14(5):125.
[21] 魏会强,郭丽萍,侯彦琨,等.慢性阻塞性肺疾病患者发生肺损伤及肺动脉高压的危险因素及血清SDF-1、sRAGE的预测价值[J].实用医学杂志,2023,39(24):3214-3221.
[22] 傅鸣郁,许凤,王庆文,等.中性粒细胞/淋巴细胞与心脏Tei指数诊断小儿先天性心脏病相关肺动脉高压的临床价值[J].中西医结合心脑血管病杂志,2022,20(15):2826-2831.
[23] 郭华,李扬,孙继锋.CT肺动脉成像在评价慢性阻塞性肺疾病合并肺动脉高压的应用[J].医学影像学杂志,2022,32(6):1054-1056.
[24] 张全中,鲁际.超声心动图与胸部CT在诊断COPD合并肺动脉高压分级的临床价值分析[J].中国CT和MRI杂志,2020,18(11):88-90.
[25] 董宁利,杨宏刚,黑欢欢,等.CT肺动脉造影的多参数测量联合心动超声对肺动脉高压程度的预测价值[J].西安交通大学学报(医学版),2023,44(2):275-282.
[26] 曾贞,陶沙.CT肺动脉成像联合心脏超声对肺动脉高压患者心功能损害的诊断价值[J].中国现代医学杂志,2022,32(3):87-92.
[27] 王璀瑛,陈辉,耿芳,等.COPD伴肺动脉高压患者血清HMGB1、TNF-α与病情、肺功能的相关性[J].分子诊断与治疗杂志,2023,15(4):618-621.

相似文献/References:

[1]马明铭,李 芳,杨 慧,等.噻托溴胺粉雾剂联合非药物康复方案对慢性阻塞性肺疾病患者BODE指数的影响[J].陕西医学杂志,2019,(4):515.
　MA Mingming,LI Fang,YANG Hui,et al.Effect of tiotropium bromide powder and nonpharmacological rehabilitation program on BODE index in patients with chronic obstructive pulmonary disease[J].,2019,(12):515.
[2]朱小川.血小板/淋巴细胞比值预测慢性阻塞性肺疾病急性加重期〖JZ〗伴有早期肾功能损害临床价值[J].陕西医学杂志,2019,(10):1353.
　ZHU Xiaochuan..Clinical value of platelet/lymphocyte ratio in predicting early renal impairment〖JZ〗 in acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(12):1353.
[3]张军营.吸烟对慢阻肺患者血清S100A8/A9、8异前列腺素F2α、组织蛋白酶S及其它炎症因子表达水平的影响*[J].陕西医学杂志,2019,(11):1426.
[4]焦文妤,尚家璐,李树霞△.慢性阻塞性肺疾病患者血清补体C1q肿瘤坏死因子相关蛋白5与肺功能及炎症反应相关性研究[J].陕西医学杂志,2019,(12):1616.
[5]陈辅萍.慢性阻塞性肺疾病并发感染性肺炎危险因素分析[J].陕西医学杂志,2020,49(1):102.
[6]薛佩妮,冯敏娟△,王惠琴.噻托溴铵粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响*[J].陕西医学杂志,2020,49(2):216.
　XUE Peini,FENG Minjuan,WANG Huiqin..Efficacy of tiotropium bromide combined with glucocorticoids in the treatment of COPD and its effect on patients' quality of life score[J].,2020,49(12):216.
[7]焦文妤,高爱华△.血清可溶性髓系细胞触发受体-1与临床肺部感染评分在慢性阻塞性肺疾病呼吸机相关性肺炎早期诊断及预后判断中的效能研究[J].陕西医学杂志,2020,49(12):1630.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.024]
　JIAO Wenyu,GAO Aihua..Effectiveness of sTREM-1 and CPIS in early diagnosis and prognosis judgment of ventilator-associated pneumonia in COPD[J].,2020,49(12):1630.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.024]
[8]张卓红,赵拖利.慢性阻塞性肺疾病大鼠血液、支气管灌洗液中水通道蛋白及p-c-Jun-N-末端激酶表达情况实验研究[J].陕西医学杂志,2021,50(7):776.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.002]
　ZHANG Zhuohong,ZHAO Tuoli.Expression of AQP-1 and p-JNK in blood and bronchial lavage fluid of rats with COPD[J].,2021,50(12):776.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.002]
[9]余 刚,张飔雪.慢性阻塞性肺疾病急性加重期患者血清干扰素-γ、甲壳质酶蛋白-40水平及与预后、肺功能相关性分析[J].陕西医学杂志,2021,50(10):1223.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.011]
　YU Gang,ZHANG Sixue.The levels of INF-γ and YKL-40 in patients with AECOPD and their correlation with prognosis and lung function[J].,2021,50(12):1223.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.011]
[10]曾德优,张六一,肖 创,等.慢性阻塞性肺疾病动物模型研究进展[J].陕西医学杂志,2022,51(4):507.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.029]
　ZENG Deyou,ZHANG Liuyi,XIAO Chuang,et al.Research progress on animal models of chronic obstructive pulmonary disease[J].,2022,51(12):507.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.029]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(S2020-YF-YBSF-1186)
更新日期/Last Update: 2024-12-05